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Context. Dying patients commonly experience potentially distressing symptoms. Palliative care guidelines recommend
opioids, anticholinergics, antipsychotics, and benzodiazepines for symptom relief.
Objectives. The objective of this study was to systematically review the effectiveness and safety of palliative drug treatment
in the last days of life of adult patients, focusing on the management of pain, dyspnea, anxiety, restlessness, and death rattle.
Methods. A systematic search of the literature was published before December 2016 in PubMed/MEDLINE, Embase,
CINAHL, PsycINFO, Cochrane, ClinicalTrials.gov, and SveMedþ. Studies on safety or effectiveness of drug therapy in dying
adults with at least one outcome on symptom control, adverse effects, or survival were included. Data for included studies were
extracted. Study quality was assessed using the Effective Public Health Practice Quality assessment tool for quantitative studies.
Results. Of the 5940 unique titles identified, 12 studies met the inclusion criteria. Five studies assessed anticholinergics for
death rattle, providing no evidence that scopolamine hydrobromide and atropine were superior to placebo. Five studies
examined drugs for dyspnea, anxiety, or terminal restlessness, providing some evidence supporting the use of morphine and
midazolam. Two studies examined opioids for pain, providing some support for morphine, diamorphine, and fentanyl. Eight
studies included safety outcomes, revealing no important differences in adverse effects between the interventions and no
evidence for midazolam shortening survival.
Conclusion. There is a lack of evidence concerning the effectiveness and safety of palliative drug treatment in dying patients,
and the reviewed evidence provides limited guidance for clinicians to assist in a distinct and significant phase of life. J Pain
Symptom Manage 2018;55:508e521. 2017 The Authors. Published by Elsevier Inc. on behalf of American Academy of Hospice and
Palliative Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Dying patients, in the last hours and days of life,
commonly experience pain, dyspnea (breathlessness),
anxiety, restlessness, and death rattle (noisy respira-
tory secretions in the dying).1e3 Patients at this stage
are often referred to as ‘‘actively dying,’’ with a clinical
presentation of waning physiological functionsAddress correspondence to: Kristian Jansen, MD, Research
Group for General Practice, Uni Research Health, Kalfar-
veien 31, 5018 Bergen, Norway. E-mail: jansen.kristian@
gmail.com
 2017 The Authors. Published by Elsevier Inc. on behalf of
American Academy of Hospice and Palliative Medicine. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).converging across diagnoses.4 Drug therapy, such as
opioids for pain and dyspnea, anticholinergics for
death rattle, antipsychotics for agitated delirium, and
benzodiazepines for anxiety, is recommended in palli-
ative care guidelines internationally.5e13
The dying patient is affected by a state of physiolog-
ical multiorgan failure, which in a number of ways mayAccepted for publication: June 21, 2017.
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therapy.14 Patients may additionally be unable to self-
report symptoms or participate in treatment decisions
due to reduced consciousness, and proxy assessments
based on observations of physical and behavioral fac-
tors may diverge from patient experience.15 Lastly,
palliative drug therapy for dying patients should
neither prolong suffering nor shorten life.16
The effectiveness and safety of drug therapy used for
palliation in the dying patient have been most exten-
sively studied in patients with terminal cancer. Extrapo-
lation of data from populations with cancer to other
populations has a number of issues. Most patients die
from conditions other than cancer.17 The illness trajec-
torymay bemoreunpredictable innonmalignant condi-
tions,18 with unique patterns of distress19 affecting
prognostication20 and treatment.21 Adding complexity
to this, the choice to use palliative drug therapy is not
only a purely medical decision but typically subject to
shared decision making22 under the influence of inter-
personal, psychological, organizational, andcultural fac-
tors. For example, initiationofdrug treatmentat theend
of life is affectedbynegotiations with thepatient’s family
and the physician’s own existential encounter with
death.23 Dialogue between doctor, staff, patient, and
family to adjust aims of treatment and care and to sup-
port shared decision making is known as Advance Care
Planning,24,25 a process which may or may not result in
written directives specifically instructing treatment,
often referred to as ‘‘advance directives,’’26 ‘‘living wills,’’
or ‘‘physician/medical treatment orders.’’27
The 2015 NICE guidelines on Care of dying adults
in the last days of life5 reviewed comparative studies
on symptomatic drug treatment in the last 14 days of
life. The NICE guidelines report one study on drug
treatment of pain, three studies on breathlessness,
three studies on nausea, and eight studies on respira-
tory tract secretions. However, for the treatment of
other common symptoms in dying persons, such as
anxiety, delirium, or agitation, no evidence is provided
in the NICE guidelines or in two earlier Cochrane re-
views on a broader palliative care population.28,29
This study aims to systematically review the effective-
ness and safety of palliative drug treatment in the last
days of life of adult patients, focusing on the manage-
ment of pain, dyspnea, anxiety, restlessness, nausea,
and death rattle.Methods
This study was registered in the PROSPERO Inter-
national prospective register of systematic reviews
(CRD42016029236) and conducted in accordance
with the PRISMA guidelines (see Appendix 1 for the
PRISMA checklist).Search Strategy
We conducted a systematic search in PubMed/MED-
LINE, Embase, CINAHL, PsycINFO, Cochrane,
ClinicalTrials.gov, and SveMedþ. The search strategy
(see Appendix 2 for the Search strategy) was adapted
from a strategy presented in the 2015 NICE Guidelines
Care of the dying adult (A.2.1 Recognizing dying).5 In
addition, we hand-searched the reference lists of all
included articles and relevant literature reviews.
Inclusion/Exclusion Criteria
Studies were included in the review if they used an
experimental or quasi-experimental design (clinical
trial, cohort, or case-control) to examine the effective-
ness or safety of palliative drug therapy in adults
($18 years) in their last two weeks of life or clinically
considered dying. All settings, countries, and diagno-
ses were included. Any comparison groups, or the
lack of, were accepted. Qualitative studies, case re-
ports, cross-sectional studies, opinion pieces, and con-
ference abstracts were excluded. We did not restrict
our search by publication date, as we anticipated few
high-quality studies. Studies were restricted to English,
Spanish, German, French, Norwegian, Swedish,
Danish, and Dutch languages, for the authors to be
able to assess them. Studies that did not focus on
the specified primary or secondary outcomes of inter-
est listed subsequently were excluded.
Outcomes of Interest
 Primary outcomes: symptom or symptom control
measures regarding pain, dyspnea, anxiety, rest-
lessness, and death rattle; number or degree of
adverse effects; and mortality or survival.
 Secondary outcomes: level of consciousness, func-
tional level, quality of life, and quality of care.Study Selection and Data Extraction
After removal of all duplicates, studies were evalu-
ated in a stepwise procedure for inclusion in the re-
view (Fig. 1). All titles identified in the search were
screened for eligibility. For those titles considered
potentially eligible, the abstracts were screened inde-
pendently by two authors (K. J. and L. P.), using the
inclusion criteria specified earlier. The full text of all
articles meeting these criteria was assessed indepen-
dently by pairs of authors (K. J. and D. F. H., K. J.
and L. P., or K. J. and S. R). For the 12 articles meeting
the inclusion criteria, data extraction was performed
using the McMaster Critical Review Form for quantita-
tive studies.30 Additional information on health care
setting, time before death studied, diagnostic category,
drug category, and drug administration route was also
extracted. To test the study selection and data
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Fig. 1. PRISMA diagram of study selection.
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extraction were made by all authors on five studies.
Discrepancies were resolved via discussion between
author pairs until agreement or referred to at least
one other review author for consensus.Quality Assessment
The quality of the 12 studies included in the review
was assessed using the Effective Public Health Practice
Quality assessment tool for quantitative studies.31 This
tool was chosen for its applicability across a wide range
of quantitative study designs. Studies were rated weak,
moderate, or strong on the following six components:
selection bias, study design, confounders, blinding,data collection, and withdrawal. The quality ratings
across the six domains were aggregated to give a global
rating for each study as follows: weak (two or more
component weak ratings), moderate (one weak rat-
ing), or strong (no weak ratings). Quality assessments
were scored independently by three authors (K. J.,
D.F.H., and S.R.), and discrepancies discussed until
consensus was reached. Bias was further discussed at
an outcome level where considered relevant.Results
Final search date was December 21, 2016. Our
search identified 5923 records. After removal of 1720
Vol. 55 No. 2 February 2018 511Drug Safety and Effectiveness in the Dyingduplicates, we screened 4203 unique titles and 819
potentially relevant abstracts, yielding 70 records that
met the inclusion criteria. Following full-text assess-
ment of these, nine articles were included for data
extraction. Hand searching the reference lists of the
included studies and those of 18 systematic reviews
and five review articles identified in the initial search,
we identified three additional studies,32e34 for a total
of 12 studies (Fig. 1). Heterogeneity of studies did
not allow for meta-analysis.Study Characteristics
The 12 studies included for data extractionwere pub-
lished between 1977 and 2016 (Table 1). Eight studies
were performed in Europe,32e39 two in North
America,40,41 one in Asia,42 and one in South
America.43 Seven studies were randomized controlled
trials (RCTs),32e36,40,43 four were prospective cohort
studies,37,38,41,42 and one a retrospective cohort study.39
Eight studies were set in palliative care units or
hospices,34e41 with one of these also including home
care patients.41 The remaining four studies were set at
nonspecialist palliative care hospital wards.32,33,42,43
All studies were either exclusively or predominantly
conducted in patients with a main diagnosis of cancer.
The time before death studied was, in all studies except
one where it was not reported,40 either expressed in
terms of time from study entry to deathor as a life expec-
tancy estimate (Table 1).
The studies included a range of different palliative
drug treatments. Five studies investigated
anticholinergics,32,35e37,40 five studies opioids,33,34,39,42,43
three studies benzodiazepines,33,38,43 and one studyTable
Characteristics of I
First Author, Year, Country Setting
Heisler et al., 2013, U.S. PCU
Likar et al., 2002, Germany Hospital Lung department Gyn. d
and Pain Clinic
Likar et al., 2008, Austria/Germany PCU/Hospital Lung department
Wildiers et al., 2009, Belgium PCU
Back et al., 2001, U.K. PCU
Navigante et al., 2003, Argentina Hospital Oncology ward
Navigante et al., 2006, Italy Cancer Institute
Mercadante et al., 2009, Italy PCU
McIver et al., 1994, U.S. Palliative Care Service inpatients a
Hospice Home Care Service
outpatients
Pang et al., 2016, Singapore Cancer hospital
Twycross, 1977, U.K. Hospice
Ellershaw et al, 2002, U.K. PCU
PCU ¼ Palliative Care Unit; NR ¼ not reported; LCP ¼ Liverpool Care Pathway finvestigated an antipsychotic41; sevenof the studies evalu-
atedmore than one drug.33e37,39,43 Five studies looked at
death rattle,32,35e37,40 five studies at dyspnea,33,38,41e43
and two studies looked at pain.34,39 Three of the studies
on dyspnea also investigated restlessness,41 delirium,38
or anxiety.43 Overall, seven included studies reported
on adverse effects,33e36,40,42,43 and three studies reported
comparatively on survival.33,36,38 Data on all primary out-
comes (symptom control, adverse effects, and survival)
were identified. The only secondary outcome discussed
in the included studies was level of consciousness. No
data on impact of palliative drug therapy on functional
level, quality of life, or quality of care were identified.
Quality Assessment
The Effective Public Health Practice global rating
scores for the quality of the included articles are pre-
sented in Table 2. Two articles were rated as ‘‘strong,’’
seven articles were rated ‘‘moderate,’’ and three articles
were rated ‘‘weak.’’ The most common weak compo-
nent ratings were for confounders,33,39,41,42 data collec-
tion,39,41,43 blinding,36,38,42 and withdrawal.34,35,42
Death Rattle
Study Characteristics. Five studies examined the effec-
tiveness of anticholinergics for death rattle (Table 3).
The drugs studied were scopolamine butylbromide,
scopolamine hydrobromide, glycopyrronium hydrobro-
mide, and atropine. Four studies were RCTs,32,35,36,40
two of which were placebo controlled,32,40 and one of
which was a pilot RCT35; one study had a prospective
cohort design.37 Study quality was assessed as strong in
two studies37,40 and moderate in three.32,35,36 Three1
ncluded Studies
Diagnosis Time Before Death Studied
Any (43% cancer) NR
ept. Cancer ‘‘Terminal’’ patients
Cancer Life expectancy <3 wk
Cancer (95%) Median survival 23.9 h, mean survival
39.2 h. All died within 350 h.
Cancer (98%) 5 mine5 d from study entry to death
Cancer Life expectancy < 1 wk
Cancer Life expectancy < 1 wk
Cancer Median duration of sedation 22 h
(2e160 h), mean admission time
6.6 d (range 1e15 d)
nd Cancer Life expectancy <48 h, median time
patients received chlorpromazine
(recorded for 15/20) was 1 day
(range le5)
Cancer Mean survival from study entry 7 d
Cancer Median survival at unit less than 2 wk.
About 50% of patients died within a
week.
Cancer All patients less than 10 d on the LCP
or Care of the Dying Patient.
Table 2
EPHPP Quality Assessment of Included Studies
Author, Year Selection Bias Study Design Confounders Blinding Data Collection Withdrawal Global Rating
Heisler et al., 2013 2 1 1 2 2 1 1
Likar et al., 2002 2 1 1 1 2 3 2
Likar et al., 2008 2 1 1 1 2 1 2
Wildiers et al., 2009 2 1 1 3 2 1 2
Back et al., 2001 2 2 1 2 2 1 1
Navigante et al., 2003 2 1 1 2 3 1 2
Navigante et al., 2006 2 1 3 2 1 2 2
Mercadante et al., 2009 2 2 1 3 2 1 2
McIver et al., 1994 2 2 3 2 3 2 3
Pang et al., 2016 2 2 3 3 2 3 3
Twycross, 1977 2 1 1 2 2 3 2
Ellershaw et al., 2002 2 2 3 2 3 2 3
Component ratings are given as 1 ¼ strong, 2 ¼ moderate, 3 ¼ weak.
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et al.37 to assess the severity of death rattle (0, inaudible;
1, audible only very close to thepatient; 2, clearly audible
at the end of the bed, in a quiet room; 3, clearly audible
at about 20 ft [9.5 m], in a quiet room).Comparison With Placebo. No drugs tested against pla-
cebo (scopolamine hydrobromide and atropine) were
found to be superior to placebo. A placebo-controlled
RCT from the U.S. comparing sublingual atropine to
sublingual saline in 160 patients found no difference
in noise score and heart rate at baseline, after
two hours (P ¼ 0.73) and four hours (P ¼ 0.21).40 A
smaller placebo-controlled study from Germany
compared intravenous (i.v.) or subcutaneous (s.c.)
scopolamine hydrobromide to saline in 31 patients
and likewise found no significant difference in death
rattle scores (P value not reported).32Comparison Between Drugs. Three head-to-head studies
compared the effectiveness of different anticholiner-
gics, with conflicting evidence regarding comparative
effectiveness. A small double-blinded pilot RCT from
Germany (n ¼ 13) comparing the effect of i.v. scopol-
amine hydrobromide and glycopyrronium found
significantly less death rattle with glycopyrronium.35
No difference in restlessness and expressions of pain
was found between the two groups. Neither of the two
German studies were powered to show a difference be-
tween groups, and results were presented as figures,
with no percentages shown.32,35 An RCT from Belgium
(n¼ 333) revealed that s.c. atropine, scopolaminebutyl-
bromide, and scopolamine hydrobromide reduced
noise score in around 40% of cases, with no significant
difference between the drugs.36 In considering this
outcome, it should be noted that the study was not
blinded, and there was no systematic recording of intra-
venous and oral fluid intake, which could have influ-
enced the development of the death rattle. A
prospective cohort study from the U.K. (n ¼ 170)revealed significantlymore patients with reduced death
rattle noise scores 30 minutes after injection of scopol-
amine butylbromide (P¼ 0.002) and less need for a sec-
ond injection (P ¼ 0.03) compared with
glycopyrronium.37 The dose of glycopyrronium was
not quite equipotent (0.20 mg given, 0.27 mg needed)
to the scopolamine butylbromide dose, possibly influ-
encing the findings. No important differences in
adverse effects or survival were noted in the studies,
although the Belgian study noted a temporarily
decreased consciousness with scopolamine hydrobro-
mide compared with atropine and scopolamine butyl-
bromide after 12 hours (P ¼ 0.0076) but not after
24 hours.Dyspnea
Study Characteristics. Five studies investigated the
effectiveness of drug therapy for dyspnea, either
alone33,42 or in combination with anxiety,43 agitated
delirium38 or terminal restlessness.41 Three of the
studies reported also on safety outcomes
(Table 2).33,42,43 Drugs studied were the opioids
morphine33,43 and fentanyl,42 the benzodiazepinemid-
azolam,33,38,43 and the antipsychotic chlorpromazine.41
Two studies were RCTs33,43 and three were prospective
cohort studies.38,41,42 Study quality was assessed as
weak in two studies41,42 and moderate in three.33,38,43Morphine and Midazolam for Dyspnea. Some evidence
was found to support the use of morphine and midazo-
lam for dyspnea. An RCT from Argentina (n ¼ 51)
compared s.c. morphine plus midazolam (MM) vs. oxy-
gen.43 Based on a Verbal Rating Scale, significant dys-
pnea improvement was found in both groups, in favor
of MM at 24 hours (P ¼ 0.03). Nausea was reported
for both groups. AnRCT fromItaly (n¼ 101) also found
more patients experiencing dyspnea relief according to
a modified Borg scale in the continuous s.c. MM group
compared with the morphine (P¼ 0.03) or midazolam
(P ¼ 0.0004) alone groups after 24 hours, a benefit
Table 3
Safety and Effectiveness of Interventions
First Author,
Year, Country Indication Drug Category Design Outcome Measure
Overall
Sample
Size (n) Intervention Effectiveness Safety Qualitya
Heisler,
2013, U.S.
Death
rattle
Anticholinergic
(atropine)
Double-blind
RCT
Reduction of death
rattle score by Back
et al. (0e3) by one
point or more,
assessed at start and
after 2 and 4 h
160 1) Atropine (n ¼ 74)
1 mg sublingually (two
drops of 1% solution)
2) Placebo (n ¼ 63)
Two drops of placebo
(saline) solution
sublingually
No difference between
groups
Effectiveness after 2 h;
38%, 41% (P ¼ 0.73)
Effectiveness after 4 h;
40%, 52% (P ¼ 0.21)
No significant
difference in heart
rate
Strong
Likar, 2002,
Germany
Death
rattle
Anticholinergic
(scopolamine
hydrobromide)
Double-blind
RCT
Death rattle score
(1e5) assessed
every 2 h
31 1) Scopolamine
hydrobromide
(n ¼ 15) 0.5 mg i.v. or
s.c. at 0, 4, and 8 h
2) Placebo (n ¼ 16)
1 mL saline solution i.v.
or s.c. at 0, 4, and 8 h
No difference between
groups
Results presented in
figures; percentages
and P unknown
NR Moderate
Likar, 2008,
Austria/
Germany
Death
rattle
Anticholinergic
(scopolamine
hydrobromide,
glycopyrronium
hydrobromide)
Double-blind
RCT, pilot
Death rattle score
(1e5) assessed
every 2 h
13 1) Scopolamine
hydrobromide
(n ¼ 7) 0.5 mg i.v. at
0, 6, and 12 h
2) Glycopyrronium
bromide (n ¼ 6)
0.4 mg i.v. at 0, 6, and
12 h
Glycopyrronium
bromide group
responded more
often than
scopolamine
hydrobromide group
at 2 h (P ¼ 0.029)
and 12 h (P ¼ 0.003).
Results presented as
figures, percentages
unknown
No difference in side
effects
Moderate
Wildiers
et al., 2009,
Belgium
Death
rattle
Anticholinergics
(atropine,
scopolamine
hydrobromide,
scopolamine
butylbromide)
RCT Lowering of death
rattle score by Back
et al. (0e3) to 0 or
1, assessed at start
and after 30 min,
one, four, 12, 24 h,
and then every 24 h
until death.
Side effects
333 1) Atropine (n ¼ 115)
0.5 mg s.c. bolus,
followed by 3 mg/
24 h
2) Scopolamine
hydrobromide
(n ¼ 112)
0.25 mg s.c. bolus,
followed by 1.5 mg/
24 h
3) Scopolamine
butylbromide
(n ¼ 106)
20 mg s.c. bolus,
followed by 60 mg/
24 h
No difference between
groups
Effectiveness after 1 h;
42%, 37%, and 42%
(P ¼ 0.72)
Effectiveness after 24 h;
76%, 68%, and 60%
(NS; P ¼ NR)
Consciousness
decreased more with
scopolamine
hydrobromide after
12 h (P ¼ 0.0076) but
not after 24 h. No
differences in pulse,
temperature, and
confusion. No
difference in survival.
Moderate
Back et al.,
2001, U.K.
Death
rattle
Anticholinergics
(scopolamine
butylbromide,
glycopyrronium
hydrobromide)
Prospective
cohort
Death rattle score
by Back et al. (0e3)
after 30 min, 1 h,
and last score before
death were compared
with the initial score
170 1) Scopolamine
butylbromide
(n ¼ 108) 0.4 mg s.c.
2) Glycopyrronium
bromide(n ¼ 62)
0.2 mg s.c.
Scopolamine
hydrobromide gave
reduced noise score
after 30 min
compared with
glycopyrronium
NR Strong
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Continued
First Author,
Year, Country Indication Drug Category Design Outcome Measure
Overall
Sample
Size (n) Intervention Effectiveness Safety Qualitya
and categorized as
better, the same,
or worse.
bromide (P ¼ 0.002)
and less need for a
second injection
(P ¼ 0.03)
No significant
difference after 1 h
and on last recorded
score.
Navigante
et al., 2003,
Argentina
Dyspnea
and
anxiety
Opioid (morphine),
benzodiazepine
(midazolam)
RCT Dyspnea and anxiety
intensity (VRS),
assessed at start
and after 20 min
and 24 h.
Number of respiratory
panic attacks. Nausea
and somnolence
(0e4)
51 1) Morphine (n ¼ 25)
2.5e5 mg/4 h s.c. plus
midazolam (MM
group) s.c. 7.5 mg if
dyspnea score >5
2) Oxygen (n ¼ 26)
4e6 L/min on mask
Improvement in
dyspnea for both
groups at 20 min and
24 h, MM group
better than oxygen at
24 h (P ¼ 0.03)
Improvement in anxiety
for both groups at
20 min, after 24 h
only in the MM group
(P ¼ 0.035), MM
group better than
Oxygen both at
20 min (P ¼ 0.024)
and 24 h (P ¼ 0.032)
Only nausea reported
for both groups, 12%
in MM group, 15.4%
in oxygen group
(P ¼ NR), no
difference in oxygen
saturation (P ¼ NR)
Moderate
Navigante
et al., 2006,
Italy
Dyspnea Opioid (morphine),
benzodiazepine
(midazolam)
RCT Dyspnea intensity
(modified Borg scale)
and relief (y/n)
assessed every 4 h.
Episodes of
breakthrough
dyspnea (BD),
frequency, and
severity (1e4) of
side effects. Survival
101 1) Morphine (n ¼ 35)
2.5 mg/4 h
continuous s.c.,
adjusted if baseline
opioids, with
midazolam rescue
doses (5 mg) in case
of BD
2) Midazolam (n ¼ 33)
5 mg/4 h continuously
s.c. with morphine
rescues (2.5 mg) in
case of BD
3) Morphine 2.5 mg/4
h plus midazolam
5 mg/4 h s.c.
(n ¼ 33) with
morphine rescue
doses (2.5 mg) in
case of BD
Morphine plus
midazolam relieved
dyspnea significantly
better than
midazolam and
morphine alone at 24
hours (Mo, Mi, MM);
69%, 46%, 92% (MM
vs. Mi, P ¼ 0.0004;
MM vs. Mo, P ¼ 0.03),
after 48 hours only
compared to Mi
(P ¼ 0.04)
Breakthrough dyspnea
(Mo, Mi, MM); 34%,
36%, 21% (NS;
P ¼ NR)
Group 1 had more cases
of distressing side
effects (11 of 17)
compared with the
other two groups
(both three of 17)
(P ¼ 0.0324), most
commonly
somnolence. No
significant difference
in survival (P ¼ NR)
Moderate
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Mercadante
et al., 2009,
Italy
Dyspnea
and
terminal
restlessness
Benzodiazepine
(midazolam)
Prospective
cohort
Level of sedation
(Communication
Capacity Scale,
0e5), assessed every
6 h. Agitated delirium
(0e3) at regular
intervals. Survival.
77 (42)b 1) Midazolam (n ¼ 42)
Continuous i.v., starting
dose around 30e
45 mg/day and then
adjusted according to
the clinical
circumstances
2) Not on midazolam
sedation regimen
(n ¼ 35)
Level of sedation
increased (P < 0.05)
and agitated delirium
decreased
P ¼ 0.0001) with
increasing doses of
midazolam
Sedated patients
survived longer than
those not sedated
(P ¼ 0.003)
Moderate
McIver
et al., 1994,
U.S.
Dyspnea and
terminal
restlessness
Antipsychotic
(chlorpromazine)
Prospective
cohort,
uncontrolled
Level of arousal
(1e4), restlessness
(1e4), and dyspnea
alleviation (none/
partial/complete)
assessed within 24 h
and then every 24 h
until death
20 Chlorpromazine
(n ¼ 20)
i.v. (median dose
12.5 mg/24 h) or
rectally (median dose
25 mg/24 h)
Complete symptom
relief before death,
18/20
Partial symptom relief,
2/20
Only initial level of
arousal was recorded
NR Weak
Pang et al.,
2016,
Singapore
Dyspnea Opioid (fentanyl) Prospective
cohort,
uncontrolled
Lowering of
self-reported
dyspnea severity
(mild, moderate,
severe) after 24 h
compared with at
infusion start.
16 Fentanyl (n ¼ 16) i.v.
(median dose 7.5 mg/
h in the responder
and 12 mg/h in the
nonresponder
groups)
No significant
difference at 24 h
(nonresponders vs.
responders ¼ 56.3%
vs 43.8%, P ¼ 0.33)
Few side effects.
Myoclonic jerks or
pruritus (one
patient), nausea, and
vomiting or
nightmares (two
patients)
Weak
Twycross,
1977, U.K.
Pain Opioids (morphine,
diamorphine)
Double-blind
crossover RCT
Pain, nausea, mood
(100 mm VAS)
assessed twice daily.
Sleep, appetite
(100 mm VAS), and
constipation/need
for laxative assessed
daily
146 1) Diamorphine
hydrochloride, oral
(doses NR)
2) equipotent (1:1.5)
oral morphine sulfate
(doses NR)
For both groups, drugs
were given in elixir
with cocaine
hydrochloride 10 mg,
opioid titrated until
pain free. Concurrent
antiemetic
prochlorperazine or
chlorpromazine
(doses NR)
Male patients receiving
diamorphine
experienced more
pain (16.8 mm
difference between
group means,
P < 0.01).
No significant
difference for female
patients
Male patients receiving
diamorphine had
worse mood score
(12.5 mm difference,
P < 0.01) compared
with those receiving
morphine, whereas
no significant
difference for female
patients. No
difference in
constipation and
vomiting
Moderate
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.which after 48 hours only stayed significantly different
compared to midazolam alone (P ¼ 0.04).33 Somno-
lence was more frequent in the morphine group. Navi-
gante et al. attribute the somnolence to the frequent
episodes of breakthrough dyspnea in this group being
treated by higher doses of midazolam compared with
the two other groups, in the form of frequent midazo-
lam rescue doses. This study also had a high attrition
rate due to deaths within the observation period of
48 hours (31 of 101). No significant difference in sur-
vival between the groups was noted.
Fentanyl for Dyspnea. A small uncontrolled prospec-
tive cohort study from Singapore (n ¼ 16) found no
effectiveness of i.v. fentanyl to relieve dyspnea.42 Based
on self-reported dyspnea severity after 24 hours
compared with severity at infusion start, no significant
difference was found between the proportion of non-
responders vs. responders (56.3% vs 43.8%, P ¼ 0.33).
Few adverse effects were reported. Although five pa-
tients did not die within the same hospital admission,
mean survival for deceased patients was seven days.
Also, 20 patients dropped out, being too ill to self-
report symptoms, or dying before 24 hours, rendering
this a dying population for the purposes of this study.
Anxiety
Some evidence was also found to support the use of
morphine and midazolam for anxiety. The earlier
mentioned RCT from Argentina (n ¼ 51) compared
s.c. MM vs. oxygen for anxiety.43 An improvement in
anxiety was observed for both groups at 20 minutes,
but after 24 hours only in the MM group (P ¼ 0.035).
MM performed better than oxygen both at 20 minutes
(P ¼ 0.024) and 24 hours (P ¼ 0.032).
Terminal Restlessness
Two studies investigated the effectiveness of drug
therapy on agitated delirium or terminal restless-
ness.38,41 A prospective cohort study from Italy sup-
ported the use of midazolam for agitated delirium.38
Continuous i.v. midazolam given as a sedation
regimen in 42 patients gave less symptoms
(P ¼ 0.0001) with increasing drug doses.38 There
was no control group for the effect outcomes and we
assessed the study quality as weak. Survival from admis-
sion in patients sedated with midazolam was longer
compared with a control group that was not sedated
(P ¼ 0.003), but details of the drug treatment and
the condition of unsedated patients were not re-
ported, and there may have been a selection bias.
An uncontrolled prospective cohort study for the
effectiveness of i.v./rectal chlorpromazine sedation
on dyspnea (10 patients) and restlessness (10 patients)
included both palliative care inpatients and outpa-
tients in the U.S. The study did not discriminate
Vol. 55 No. 2 February 2018 517Drug Safety and Effectiveness in the Dyingeffectiveness results with respect to the two symptoms
included, but reported complete symptom relief in 18
of 20 patients and partial relief in two of 20 patients
before death.41 Although McIver et al. concluded
that chlorpromazine is highly effective, the lack of
control group opens for confounding, data collection
tools lacked reliability and validity, and study size was
small.
Pain
Our review includes two studies specifically investi-
gating treatment of pain in the dying.34,39 Overall,
there appears to be little evidence supporting drug
treatment for pain in the dying. Oral morphine was su-
perior to oral diamorphine in controlling pain in male
patients in one RCT,34 and fentanyl patches were more
effective than intravenous diamorphine in a retrospec-
tive cohort study.39 However, the differences between
groups were likely explained by confounders in both
studies. In the crossover RCTon 146 patients, male pa-
tients had more pain (16.8 mm difference between
group means as measured on a Visual Analogue Scale,
P < 0.01) and worse mood score (12.5 mm difference,
P < 0.01) when given diamorphine compared with
when given morphine.34 No difference was found for
female patients, and results across genders were not
reported. The doses of the two agents were according
to the authors probably not equipotent, with 1.5 mg
diamorphine hydrochloride compared with 1 mg
morphine sulfate. Furthermore, there was a high attri-
tion rate in the study with only 21% (n ¼ 146 of 699)
of participants crossing over to receive a second agent.
A retrospective cohort study comparing the effect of a
fentanyl patch vs. diamorphine in a syringe driver in
94 patients reported better pain control at 20 hours
and eight hours compared with the diamorphine
group. In addition, the fentanyl group used fewer
‘‘as required’’ opioid doses on the last day of life
(P ¼ 0.001).39 Both groups had good pain control in
the last 48 hours of life. Patients having fentanyl
patches received approximately twice the equianalge-
sic dose of those receiving diamorphine and although
patients were matched for age, sex, and diagnosis, fen-
tanyl patches were considered a second-line treat-
ment, indicating that patients treated with fentanyl
patches may have had more complex pain.Discussion
This systematic review shows that despite routine
use of palliative drug therapy for symptom control in
dying adults, there is little evidence regarding the
effectiveness and safety of the commonly used agents.
Twelve studies examining the effectiveness (n ¼ 12)
and safety (n ¼ 8) of palliative drug therapy across arange of symptoms were reviewed. Despite including
both experimental and quasi-experimental designs,
the included studies were small scale and only two
were considered to be of strong quality, further
limiting their contribution to the evidence base of
palliative drug therapy in dying adults.
Death Rattle
No evidence supporting the use of anticholinergics
for death rattle was found. Our review found that an-
ticholinergics were no better than placebo for
reducing death rattle. Similar findings have been pre-
viously reported in two reviews.5,44 Our review high-
lights possible safety concerns associated with using
scopolamine hydrobromide compared with atropine
and scopolamine butylbromide, in the form of tempo-
rarily decreased consciousness. Death rattle is a symp-
tom with uncertain impact on the patient, not
associated with respiratory distress in the patient45
but difficult to endure for family and staff.46,47 In
absence of evidence and with uncertainty regarding
the need for its treatment, reassuring communication
with next-of-kin may be preferable.44,48,49
Dyspnea
In this review, we found some evidence regarding
the use of morphine and midazolam, especially in
combination, for management of dyspnea in dying pa-
tients. Our results support those previously reported
in the NICE review of 2015. Although we found
some evidence for morphine/midazolam, no evidence
supporting the use of fentanyl was found. A single pro-
spective cohort study examining the use of i.v. fentanyl
was included in the review.42 No significant response
to i.v. fentanyl was reported, but the uncontrolled
study design may weaken the strength of this conclu-
sion and further studies are needed. Looking at a
broader palliative care population and not just the
actively dying patient, two recently updated Cochrane
reviews have found no evidence supporting the use of
benzodiazepines for the relief of breathlessness in
people with advanced cancer and chronic obstructive
pulmonary disease50 and only some low-quality evi-
dence showing benefit of oral or parenteral opioids
to palliate breathlessness.51
No major safety concerns regarding the use of
morphine, midazolam, or fentanyl for dyspnea in
the dying were identified in this review. Adverse effects
associated with using palliative drug therapy for dys-
pnea established in the broader palliative care popula-
tion include drowsiness, nausea and vomiting with
opioids, and somnolence with benzodiazepines.50,51
However, the safety of opioids for dyspnea relief is
further substantiated in broader palliative care popu-
lations in a 2014 systematic review, finding no compro-
mise of respiratory function.52
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Our review identified one RCT from Argentina ad-
dressing the use of palliative drug therapy for the man-
agement of anxiety in the dying patient, finding that a
combination of midazolam and morphine was more
effective than the use of oxygen.43 No studies meeting
the inclusion criteria were found in the earlier NICE
review5 nor in a Cochrane review updated in 2012
on drug therapy for anxiety in a broader palliative
care population.29Terminal Restlessness
The present review found limited evidence support-
ing the use of midazolam and chlorpromazine for ter-
minal restlessness, in two studies of palliative
sedation.38,41 Neither study reported specifically on
adverse effects, but the study by Mercadante et al. re-
ported no reduced survival associated with using mid-
azolam for palliative sedation.
A review of the evidence for treatment of delirium
or agitation in the dying by NICE in 20155 and a Co-
chrane review from 201228 also found insufficient evi-
dence to draw conclusions about the role of drug
therapy in the treatment of delirium in terminally ill
patients. A more recent Cochrane review from 2015
found limited evidence for the effectiveness of pallia-
tive sedation in terms of quality of life and symptom
control but did not differentiate between pharmaco-
logic agents.53 In line with our review, the 2015 Co-
chrane review concluded that palliative sedation
does not hasten death, a central ethical concern.Pain
A pain-free death is a central theme for patients,
family, and health care providers when defining a
‘‘good death,’’54 and pain is a common distress in
the dying.3 Our review identified only two studies ad-
dressing pain treatment in the dying. Morphine, dia-
morphine, and fentanyl patches have been studied,
but considerable confounding makes interpretation
of the results problematic, limiting their contribution
to the evidence base. Although palliative sedation may
be indicated for refractory pain, uncontrolled pain
was not an indication for sedation in the two studies
included in this review, although concomitantly pre-
sent in four of 42 patients in one of them.38 Opioid
studies in populations who are dying are challenging.
An analgesic effect of opioids is clearly expected, mak-
ing placebo-controlled groups ethically unjustified.
However, issues of altered absorption, metabolism,
and elimination of opioids in dying patients may affect
treatment effectiveness and adverse effect profiles.14,55
Further high-quality clinical trials comparing pain
treatments in the dying are warranted to guide clinical
practice regarding this critical issue.Adverse Effects and Survival
Overall, few adverse effects were reported in the ar-
ticles included in the current review, and several
studies did not report on adverse effects at all. One
explanation may be that the distinction of therapeutic
vs. adverse drug effects may be unclear in the actively
dying patient. In particular, a sedative effect may be an
adverse effect when an opioid is given to alleviate pain
but therapeutic when midazolam is given for restless-
ness or anxiety. The relative sedative impact is also
lesser if the patient’s level of consciousness is already
decreased. In addition, although some adverse effects
have obvious objective presentations, such as injection
site redness, vomiting, or respiratory depression, sub-
jective discomfort, such as nausea, may also be harder
to acknowledge in a patient with decreased
consciousness.
Although palliative drugs have known potentially
life-shortening adverse effects, typically respiratory
depression with using opioids and benzodiaze-
pines,56,57 and possibly increased mortality with using
antipsychotics,58,59 no life-shortening effect was re-
ported in the studies included in our current review.
One study reported a paradoxical prolonging of life
as with opioids used for palliative sedation.38 Similar
findings have also been reported with opioids used
for dyspnea relief60 and palliative drug therapy for
terminally ill patients in the intensive care unit.61
The effect has been attributed to the relief from
distress.60Strengths and Limitations
This review addresses the prevalent and relevant
issue of distress in the dying. The review is comprehen-
sive, including seven different databases, and employ-
ing broader inclusion criteria than has previously been
done, including cohort design studies, and articles in
seven languages in addition to English. We employed
a rigorous data extraction and quality assessment
procedure.
The present review used a clear definition of dying,
including individual studies either reporting results in
the last two weeks of life or clinically considered dying.
The same cutoff has been used in an earlier review.5
Proximity to death naturally engenders high attri-
tion rates in prospective studies, which substantially
limited the sample size in several of the included
studies.33,34,42 The facts that all studies except one
were performed in a palliative care unit or hospital,
and almost all patients had cancer, may also limit
generalizability to other patient groups and settings.
Nonmalignant conditions are more prevalent causes
of death than cancer.17,62 Although the relative lack
of studies on these patients is representative for palli-
ative care research in general, recent years has seen a
Vol. 55 No. 2 February 2018 519Drug Safety and Effectiveness in the Dyingshift in the focus toward including nonmalignant
conditions.63
Interpreting symptom outcomes in the included
studies must be done with caution for several reasons.
The proxy judgment of distress used in many of the
included studies, required in situations where patients
lack ability to self-report, is vulnerable to misinterpre-
tation.15,64,65 Patients with dementia, particularly com-
mon in the setting of nursing homes,66 may lack the
ability to self-report symptoms long before the dying
phase.67 To complicate this, drugs have multiple ef-
fects that treat several symptoms at the same time. In
the studies included in this review, midazolam, a pri-
marily sedative drug, is used for symptomatic treat-
ment for several indications such as anxiety,43
dyspnea,33,38,43 terminal restlessness, and refractory
symptoms in general.38 Overlap of symptom presenta-
tion and drug effects may make treatment strategies
simpler but complicate the design and interpretation
of intervention studies in this population. These and
other challenges considered, clinical trials in a more
broadly defined end-of-life care population have
nevertheless been shown to be feasible and even to
represent a positive experience for patients.68Conclusions
This review found limited evidence regarding the
safety and effectiveness of palliative drug therapy for
the management of commonly occurring symptoms
associated with dying. Current evidence does not sup-
port the standard use of anticholinergic drugs in the
treatment of death rattle. Some evidence supports
the use of morphine and midazolam for dyspnea, anx-
iety, or terminal restlessness. Limited evidence guides
the choice of opioids for pain.
The lack of evidence demonstrated by this review
questions our ability to effectively and safely alleviate
symptoms in a population that may respond differ-
ently to all drug treatments, and yet where patients
and family are often reassured with the argument
that this can be done. Left with few evidence-based op-
tions of intervention in the last days and hours of life,
efforts to communicate with and prepare patient and
family for the likely symptoms of the dying phase
become increasingly important. Researchers are
particularly urged to include patients with nonmalig-
nant disease in clinical trials and to conduct further
high-quality clinical trials on pain treatment in the
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Search Strategy
Database: Embase (Ovid)
Final search date: 21. December 2016
1 death/or dying/(366263)
2 terminally ill patient/or hospice patient/(8793)
3 terminal care/or hospice care/(36,872)
4 palliative therapy/or cancer palliative therapy/(92,150)
5 (dying or die* or death).ti,kw. (396362)
6 ((terminal or palliati*) adj1 care).ti,kw. (21,516)
7 ‘‘terminally ill’’.ti,kw. (2158)
8 ‘‘terminal illness’’.ti,kw. (583)
9 (palliati* adj1 stage*).ti,ab. (600)
10 (‘‘end of life’’ adj2 (stage or stages)).ti,ab. (113)
11 or/1e10 (819616)
12 ‘‘end of life’’.ti,ab. (21,783)
13 ((last or final) adj1 (hour* or day* or minute* or stage* or week* or month*)).ti,ab. (26,216)
14 ((dying or terminal) adj1 phase*).ti,ab. (2747)
15 ((dying or terminal or end) adj1 stage*).ti,ab. (79,293)
16 (dying adj2 (actively or begin* or begun)).ti,ab. (98)
17 (death adj2 (imminent* or impending or near or throes)).ti,ab. (2163)
18 ((dying or death) adj2 (patient* or person* or people)).ti,ab. (32,402)
19 (Body adj2 (shut down or shutting down or deteriorat*)).ti,ab. (165)
20 (deathbed or death-bed).ti,ab. (132)
21 or/12e20 (158358)
22 11 and 21 (47,067)
23 drug therapy/or diuretic therapy/or drug combination/(662242)
24 prescription/(161366)
25 exp anxiolytic agent/(182812)
26 exp neuroleptic agent/(250013)
27 exp benzodiazepine derivative/(169759)
28 exp antiemetic agent/(172497)
29 exp cholinergic receptor blocking agent/(168289)
30 exp diuretic agent/(333178)
31 (morphin* or opioid*).ti,ab,kw. (132265)
32 (anti-anxiety agent* or Midazolam or anxiolytic* or diazepam or oxazepam or lorazepam or benzodiazepine*).ti,ab,kw. (88,944)
33 (antiemetic* or antipsychotic* or haldol or risperidone).ti,ab,kw. (63,970)
34 (anticholinergic* or anti-cholinergic* or glycopyrronium or scopolamine or hyoscine).ti,ab,kw. (25,128)
35 (diuretic* or furosemide).ti,ab,kw. (58,694)
36 or/23e35 (1717194)
37 22 and 36 (4600)
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